15 completed. 15 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 15 |
| Phase 2 | 5 | Completed 5 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers OVX033, Saline solution - Coronavirus | Phase 1 | Completed | Osivax | 48 | 2024-01-08 | 2026-09-10 |
| A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2 LD Vehicle-GNP, LD PepGNP-Covid19, HD Vehicle-GNP - Coronavirus, SARS-CoV-2 Infection | Phase 1 | Completed | Gylden Pharma Ltd | 26 | 2022-01-10 | 2025-02-12 |
| A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 Baiya SARS-CoV-2 Vax 1 - Coronavirus | Phase 1 | Completed | Baiya Phytopharm Co., Ltd. | 48 | 2021-09-11 | 2023-01-12 |
| Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old) Recombinant new coronavirus vaccine (CHO cell) group, Recombinant new coronavirus vaccine (CHO cells) placebo group - Coronavirus | Phase 1 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 75 | 2021-07-03 | 2023-04-25 |
| A Study of Intranasal ChAdOx1 nCOV-19 ChAdOx1 nCov-19 - Coronavirus | Phase 1 | Completed | University of Oxford | 42 | 2021-04-01 | 2022-10-24 |
| Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19 Aerobic Exercise Therapy - Covid19, Coronavirus | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2021-03-29 | 2025-10-27 |
| Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control) - Covid19, Corona Virus Infection | Phase 1 / Phase 2 | Completed | Restem, LLC. | 17 | 2020-12-23 | 2024-04-09 |
| N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19) N-acetyl glucosamine (NAG), Control - Coronavirus, Covid19 | Phase 1 | Completed | Quantinosis.ai LLC | 150 | 2020-11-14 | 2023-04-04 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV Vaccine, Placebo - Severe Acute Respiratory Syndrome, Coronavirus | Phase 1 | Completed | CureVac | 280 | 2020-06-18 | 2023-01-30 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 32 | 2020-05-11 | 2021-08-23 |
| A Study of a Candidate COVID-19 Vaccine (COV001) ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost - Coronavirus | Phase 1 / Phase 2 | Completed | University of Oxford | 1077 | 2020-04-23 | 2025-09-03 |
| COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers EIDD-2801, Placebo - Coronavirus | Phase 1 | Completed | Ridgeback Biotherapeutics, LP | 130 | 2020-04-10 | 2021-07-19 |
| A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia MSCs-derived exosomes - Coronavirus | Phase 1 | Completed | Ruijin Hospital | 24 | 2020-02-15 | 2020-09-07 |
Coronavirus Infections (15) · COVID-19 (11) · Severe Acute Respiratory Syndrome (3) · Pneumonia (2) · Acute Lung Injury (1) · Lung Diseases, Interstitial (1) · Motor Activity (1) · Neoplasms (1) · Pneumonia, Viral (1) · Respiratory Distress Syndrome (1)
Coronaviridae Infections (15) · Infections (15) · Nidovirales Infections (15) · RNA Virus Infections (15) · Virus Diseases (15) · Lung Diseases (11) · Respiratory Tract Diseases (11) · Respiratory Tract Infections (11) · Pneumonia, Viral (10) · Pneumonia (9) · Behavior (1) · Lung Injury (1) · Respiration Disorders (1)
ChAdOx1 nCoV-19 (2) · Acetaminophen (1) · Acetylglucosamine (1) · Baiya SARS-CoV-2 VAX COVID-19 vaccine (1) · CVnCoV COVID-19 vaccine (1) · MenACWY (1) · Population Groups (1) · Saline Solution (1) · Standard of Care (1) · fostamatinib (1) · molnupiravir (1) · ruxolitinib (1)
University of Oxford (2) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · Apellis Pharmaceuticals, Inc. (1) · Baiya Phytopharm Co., Ltd. (1) · CureVac (1) · Gylden Pharma Ltd (1) · Imperial College London (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Memorial Sloan Kettering Cancer Center (1) · Osivax (1) · Quantinosis.ai LLC (1) · Restem, LLC. (1) · Ridgeback Biotherapeutics, LP (1) · Ruijin Hospital (1)
United Kingdom (4) · United States (4) · China (2) · Belarus (1) · Belgium (1) · Brazil (1) · France (1) · Germany (1) · Switzerland (1) · Thailand (1)
Alexander Douglas, Dr (1) · Andrei Y Hancharou, Dr. (1) · Andrew Pollard, Prof (1) · Blaise Genton, Prof. (1) · Eduard A Dotsenko, Dr., prof. (1) · Jessica Scott, PhD (1) · Jie-ming Qu, MD.,PhD. (1) · Jim Bush, MBChB, PhD (1) · Natalia G Antonevich, Dr. (1) · Nichola Cooper (1) · Odile Launay, MD (1)
PMID 32702298, PMID 33306989, PMID 33335322, PMID 33617777, PMID 33845867, PMID 34306677, PMID 34480858, PMID 35619189, PMID 36435633, PMID 36803632, PMID 37138460, PMID 40197245, PMID 40248705, PMID 41644167